Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Akebia Therapeutics (AKBA)

$6.73 0.34 (4.81%)

17:32 EDT AKBA Stock Quote Delayed 20 Minutes

Volume:

Previous Close $6.73

Market Cap 383.03M

PE Ratio -6.12

EPS -1.1

Volume (Avg. Vol.) 812,000

Day's Range 6.55 - 7.14

52-Week Range 2.99 - 10.53

Dividend & Yield N/A (N/A)

AKBA Stock Predictions, Articles, and Akebia Therapeutics News

From InvestorPlace
From the Web

5 “Strong Buy” Biotech Stocks With More Than 80% Upside

By Maya Sasson, Writer, TipRanks Nov 27, 2019

For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.

5 Healthcare Stocks That Are Down, But Not Out!

By Josh Enomoto, InvestorPlace Contributor Aug 29, 2018

Tough headwinds have impacted several healthcare stocks, presenting opportunities for risk-tolerant speculators.

Akebia Therapeutics Inc (AKBA) and Babcock & Wilcox Enterprises Inc (BW) Lead 18 Investor Reports

By Fintel May 23, 2017

13D and 13G filings are windows into activist investor activities. We look at 18 notable filings....

Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?

From Zacks Investment Research Apr 2, 2020

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

An Intrinsic Calculation For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Suggests It’s 42% Undervalued

From Simply Wall St Mar 27, 2020

In this article we are going to estimate the intrinsic value of Akebia Therapeutics, Inc. (NASDAQ:AKBA) by taking the expected future cash flows and discounting them to today’s value. I<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akba/akebia-therapeutics/news/an-intrinsic-calculation-for-akebia-therapeutics-inc-nasdaqakba-suggests-its-42-undervalued/">Read More...</a></div>

Akebia Therapeutics (AKBA) Gets a Buy Rating from Mizuho Securities

From Analyst Ratings Mar 19, 2020

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $15.00. The company’s shares closed last Monday at $4.10, close to its 52-week low of $2.99. According to TipRanks.com, Yang ‘s ranking currently consits of no stars on a

Biotechs update on product supply amid coronavirus outbreak

From Seeking Alpha Mar 16, 2020

In what will be routine announcements going forward, Akebia Therapeutics (NASDAQ:AKBA) and TherapeuticsMD (NASDAQ:TXMD) report that they do not anticipate any disruptions in the availability of their

Akebia files to offer up to $65M in stock

From Seeking Alpha Mar 12, 2020

Akebia Therapeutics (NASDAQ:AKBA) has registered $65M in common stock for sale. Those shares will be sold from time to time under its sales agreement with Cantor Fitzgerald. Net proceeds if any will

Akebia Therapeutics, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimates

From Simply Wall St Mar 12, 2020

Shareholders in Akebia Therapeutics, Inc. (NASDAQ:AKBA) had a terrible week, as shares crashed 26% to US$6.94 in the week since its latest full-year results. The results weren’t stellar – revenue<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akba/akebia-therapeutics/news/akebia-therapeutics-inc-just-released-its-annual-results-and-analysts-are-updating-their-estimates/">Read More...</a></div>

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy